The directors of Asarina Pharma have abandoned a search for a partner for Tourette's syndrome treatment sepranolone, saying they have no choice but to liquidate the company.
Teva’s late stage trials of a potential drug for Tourette Syndrome have drawn a blank, just when the troubled pharma needs to freshen up its portfolio.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl